secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001628280-25-011960
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Q4 net loss $191.9M; cash $383.5M; IMPT-314 pivotal trials set for mid-2025, early 2026
--------------------------------------------------------------------------------

- Net loss of $191.9M in Q4 2024 included $87.2M acquired IPR&D from ImmPACT Bio and $51.3M long-lived asset impairment.
- Cash, equivalents and marketable securities of $383.5M at Dec 31, 2024; expected to fund operations into 2027.
- IMPT-314 Phase 1/2 showed 94% ORR (16/17) and 71% complete response by 3 months; no Grade 3+ CRS in 23 patients.
- Pivotal trial for IMPT-314 in 3rd line+ LBCL expected mid-2025; 2nd line pivotal expected by early 2026.
- Non-GAAP net loss Q4 2024 was $45.9M vs $43.9M in Q4 2023; full year 2024 non-GAAP net loss $159.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/0001628280-25-011960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/lyel-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-011960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer